Home > Publications Database > Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer's disease. > print

001     155621
005     20230915092332.0
024 7 _ |a 10.1186/s13024-021-00422-x
|2 doi
024 7 _ |a pmid:33618749
|2 pmid
024 7 _ |a pmc:PMC7898440
|2 pmc
024 7 _ |a altmetric:100635728
|2 altmetric
037 _ _ |a DZNE-2021-00789
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Shafiq, Mohsin
|0 P:(DE-2719)9000295
|b 0
|e First author
245 _ _ |a Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer's disease.
260 _ _ |a London
|c 2021
|b Biomed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1691482110_15419
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a High-density oligomers of the prion protein (HDPs) have previously been identified in brain tissues of patients with rapidly progressive Alzheimer's disease (rpAD). The current investigation aims at identifying interacting partners of HDPs in the rpAD brains to unravel the pathological involvement of HDPs in the rapid progression.HDPs from the frontal cortex tissues of rpAD brains were isolated using sucrose density gradient centrifugation. Proteins interacting with HDPs were identified by co-immunoprecipitation coupled with mass spectrometry. Further verifications were carried out using proteomic tools, immunoblotting, and confocal laser scanning microscopy.We identified rpAD-specific HDP-interactors, including the growth arrest specific 2-like 2 protein (G2L2). Intriguingly, rpAD-specific disturbances were found in the localization of G2L2 and its associated proteins i.e., the end binding protein 1, α-tubulin, and β-actin.The results show the involvement of HDPs in the destabilization of the neuronal actin/tubulin infrastructure. We consider this disturbance to be a contributing factor for the rapid progression in rpAD.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Actin
|2 Other
650 _ 7 |a Co-immunoprecipitation
|2 Other
650 _ 7 |a Cytoskeleton
|2 Other
650 _ 7 |a G2L2
|2 Other
650 _ 7 |a GAS
|2 Other
650 _ 7 |a Growth arrest specific 2 like 2
|2 Other
650 _ 7 |a Growth arrest specific proteins
|2 Other
650 _ 7 |a PrPC
|2 Other
650 _ 7 |a Prion protein oligomers
|2 Other
650 _ 7 |a Rapidly progressive Alzheimer’s disease
|2 Other
650 _ 7 |a Tubulin
|2 Other
650 _ 7 |a rpAD
|2 Other
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Cytoskeleton: metabolism
|2 MeSH
650 _ 2 |a Cytoskeleton: pathology
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Prion Proteins: metabolism
|2 MeSH
700 1 _ |a Zafar, Saima
|0 P:(DE-2719)9000358
|b 1
700 1 _ |a Younas, Neelam
|0 P:(DE-2719)9001558
|b 2
|u dzne
700 1 _ |a Noor, Aneeqa
|0 P:(DE-2719)9001208
|b 3
700 1 _ |a Puig, Berta
|b 4
700 1 _ |a Altmeppen, Hermann Clemens
|b 5
700 1 _ |a Schmitz, Matthias
|0 P:(DE-2719)9000287
|b 6
700 1 _ |a Matschke, Jakob
|b 7
700 1 _ |a Ferrer, Isidre
|b 8
700 1 _ |a Glatzel, Markus
|b 9
700 1 _ |a Zerr, Inga
|0 P:(DE-2719)2000058
|b 10
|e Last author
773 _ _ |a 10.1186/s13024-021-00422-x
|g Vol. 16, no. 1, p. 11
|0 PERI:(DE-600)2244557-2
|n 1
|p 11
|t Molecular neurodegeneration
|v 16
|y 2021
|x 1750-1326
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/155621/files/DZNE-2021-00789.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/155621/files/DZNE-2021-00789_SUPP.zip
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/155621/files/DZNE-2021-00789.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:155621
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000295
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000358
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9001558
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001208
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000287
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2000058
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-05-04
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL NEURODEGENER : 2021
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-08-24T06:30:04Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-08-24T06:30:04Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-08-24T06:30:04Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-23
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-23
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b MOL NEURODEGENER : 2021
|d 2022-11-23
920 1 _ |0 I:(DE-2719)5000037
|k Ext UMG Zerr
|l Ext UMG Zerr
|x 0
920 1 _ |0 I:(DE-2719)1440011-1
|k AG Zerr
|l Translational Studies and Biomarker
|x 1
920 1 _ |0 I:(DE-2719)6000014
|k Göttingen common
|l Göttingen common
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000037
980 _ _ |a I:(DE-2719)1440011-1
980 _ _ |a I:(DE-2719)6000014
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21